1. Home
  2. Vol 29, No 2 (2025)
  3. Song

Effectiveness and safety of levofloxacin in the treatment of community-acquired pneumonia: A systematic review and metaanalysis

Fengchun Song(1), Yating Zheng(2),


(1) Department of Medicament, Pujiang Community Health Service Center of Minhang District, Shanghai,201112,China
(2) Department of Medicament,Qingdao Municipal Hospital,Qingdao,Shandong, 266011, China
Corresponding Author

Abstract


This study was conducted to evaluate the efficacy and safety of levofloxacin in the treatment of community-acquired pneumonia (CAP), and to provide a more reliable medication guide for the treatment of community-acquired pneumonia. Clinical studies of levofloxacin for CAP were searched through online literature databases, and the final literature for analysis was identified after screening by inclusion and exclusion criteria. The quality of the literature was assessed according to the risk of bias assessment criteria of the Cochrane system. Literature information was extracted and meta-analysis was performed using RevMan software. The observational indicators were clinical cure rate, microbiologic (bacteriologic) success rate, adverse event rate, and mortality rate. After screening, a total of 8 papers were included in the study, totaling 2,272 study subjects, of which 1,155 patients who received levofloxacin treatment were considered as the study group. 1117 patients who received other antimicrobial drugs were considered as the control group. The literature was evaluated to have a low risk level and a high reference value. The results of metaanalysis showed that there was no significant difference in the clinical cure rate, microbiologic (bacteriologic) success rate, adverse event rate and mortality rate between the study group and the control group (P>0.05).As a result of the study, it was concluded that: levofloxacin has significant efficacy and safety in the treatment of CAP, and other antimicrobial drugs (e.g., moxifloxacin) have comparable efficacy and higher safety than levofloxacin, which provides a more diversified solution for the treatment of CAP.

References


Sun Y, Li H, Pei Z, Wang S, Feng J, Xu L, Gao P, Cao B and Zhan

S. Incidence of community-acquired pneumonia in urban

China: A national population-based study. Vaccine, 2020.

(52): p. 8362-8370.

Herold, C.J. and J.G. Sailer. Community-acquired and nosocomial

pneumonia. Eur Radiol, 2004. 14 Suppl 3(3): p. E2-20.

Torres A, Peetermans WE, Viegi G and Blasi F. Risk factors for

community-acquired pneumonia in adults in Europe: a

literature review. Thorax, 2013. 68(11): p. 1057-65.

Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM,

Reed C, Grijalva CG, Anderson EJ, Courtney DM,

Chappell JD, Qi C, Hart EM, Carroll F, Trabue C,

Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo

K, Waterer GW, Levine M, Lindstrom S, Winchell JM,

Katz JM, Erdman D, Schneider E, Hicks LA, McCullers

JA, Pavia AT, Edwards KM and Finelli L; CDC EPIC

Study Team, Community-Acquired Pneumonia Requiring

Hospitalization among U.S. Adults. N Engl J Med, 2015.

(5): p. 415-27.

Weir DL, Majumdar SR, McAlister FA, Marrie TJ and Eurich DT.

The impact of multimorbidity on short-term events in

patients with community-acquired pneumonia:

prospective cohort study. Clin Microbiol Infect, 2015.

(3): p. 264 e7-264 e13.

Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo

S, Reyes LF, Rupp J, González Del Castillo J, Blasi F,

Aliberti S and Restrepo MI; GLIMP Investigators,

Prevalence and Etiology of Community-acquired

Pneumonia in Immunocompromised Patients. Clin Infect

Dis, 2019. 68(9): p. 1482-1493.

Arnold FW, Wiemken TL, Peyrani P, Ramirez JA and Brock GN;

CAPO authors, Mortality differences among hospitalized

patients with community-acquired pneumonia in three

world regions: results from the Community-Acquired

Pneumonia Organization (CAPO) International Cohort

Study. Respir Med, 2013. 107(7): p. 1101-11.

Heo, J.Y. and J.Y. Song, Disease Burden and Etiologic

Distribution of Community-Acquired Pneumonia in

Adults: Evolving Epidemiology in the Era of

Pneumococcal Conjugate Vaccines. Infect Chemother,

50(4): p. 287-300.

Cillóniz C, Ewig S, Polverino E, Marcos MA, Prina E, Sellares J,

Ferrer M, Ortega M, Gabarrús A, Mensa J and Torres A.

Community-acquired pneumonia in outpatients: aetiology

and outcomes. Eur Respir J, 2012. 40(4): p. 931-8.

Luna CM, Palma I, Niederman MS, Membriani E, Giovini V,

Wiemken TL, Peyrani P and Ramirez J. The Impact of Age

and Comorbidities on the Mortality of Patients of

Different Age Groups Admitted with Community-acquired

Pneumonia. Ann Am Thorac Soc, 2016. 13(9): p. 1519-

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell

GD, Dean NC, Dowell SF, File TM Jr, Musher DM,

Niederman MS, Torres A, Whitney CG; Infectious

Diseases Society of America; American Thoracic Society,

Infectious Diseases Society of America/American

Thoracic Society consensus guidelines on the

management of community-acquired pneumonia in

adults. Clin Infect Dis, 2007. 44 Suppl 2(Suppl 2): p. S27-

Levy, S.B. and B. Marshall, Antibacterial resistance worldwide:

causes, challenges and responses. Nat Med, 2004. 10(12

Suppl): p. S122-9.

Jones RN, Fritsche TR, Sader HS, Stilwell MG, Activity of

garenoxacin, an investigational des-F(6)-quinolone,

tested against pathogens from community-acquired

respiratory tract infections, including those with elevated

or resistant-level fluoroquinolone MIC values. Diagn

Microbiol Infect Dis, 2007. 58(1): p. 9-17.

Brown, S.D. and M.J. Rybak, Antimicrobial susceptibility of

Streptococcus pneumoniae, Streptococcus pyogenes and

Haemophilus influenzae collected from patients across

the USA, in 2001-2002, as part of the PROTEKT US

study. J Antimicrob Chemother, 2004. 54 Suppl 1: p. i7-

Conte JE Jr, Golden JA, McIver M, Zurlinden E, Intrapulmonary

pharmacokinetics and pharmacodynamics of high-dose

levofloxacin in healthy volunteer subjects. Int J

Antimicrob Agents, 2006. 28(2): p. 114-21.

Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX,

Tennenberg AM, Efficacy of 750-mg, 5-day levofloxacin

in the treatment of community-acquired pneumonia

caused by atypical pathogens. Curr Med Res Opin, 2004.

(4): p. 555-63.

Michaelis R, Tang V, Wagner JL, Modi AC, LaFrance WC Jr,

Goldstein LH, Lundgren T, Reuber M, Cochrane

systematic review and meta-analysis of the impact of

psychological treatments for people with epilepsy on

health-related quality of life. Epilepsia, 2018. 59(2): p.

-332.

Sun T, Sun L, Wang R, Ren X, Sui DJ, Pu C, Ren Y, Liu Y, Yang

Z, Li F, Clinical efficacy and safety of moxifloxacin versus

levofloxacin plus metronidazole for community-acquired

pneumonia with aspiration factors. Chinese Medical

Journal, 2014. 127(7): p. 1201-1205.

Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, Jamieson

BD, Fernandes P, Randomized, double-blind, multicenter

phase 2 study comparing the efficacy and safety of oral

solithromycin (CEM-101) to those of oral levofloxacin in

the treatment of patients with community-acquired

bacterial pneumonia. Antimicrob Agents Chemother,

57(6): p. 2526-34.

Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R,

Noel GJ, Comparative study of levofloxacin in the

treatment of children with community-acquired

pneumonia. Pediatr Infect Dis J, 2007. 26(10): p. 868-78.

Yuan J, Mo B, Ma Z, Lv Y, Cheng SL, Yang Y, Tong Z, Wu R,

Sun S, Cao Z, Wu J, Zhu D, Chang L, Zhang Y;

Investigator Group of the Phase 3 Study on Oral

Nemonoxacin, Safety and efficacy of oral nemonoxacin

versus levofloxacin in treatment of community-acquired

pneumonia: A phase 3, multicenter, randomized, doubleblind, double-dummy, active-controlled, non-inferiority

trial. J Microbiol Immunol Infect, 2019. 52(1): p. 35-44.

Querol-Ribelles JM, Tenías JM, Querol-Borrás JM, Labrador T,

Nieto A, González-Granda D, Martínez I, Levofloxacin

versus ceftriaxone plus clarithromycin in the treatment of

adults with community-acquired pneumonia requiring

hospitalization. Int J Antimicrob Agents, 2005. 25(1): p.

-83.

Mokabberi, R., A. Haftbaradaran, and K. Ravakhah, Doxycycline

vs. levofloxacin in the treatment of community-acquired

pneumonia. J Clin Pharm Ther, 2010. 35(2): p. 195-200.

Liu Y, Zhang Y, Wu J, Zhu D, Sun S, Zhao L, Wang X, Liu H,

Ren Z, Wang C, Xiu Q, Xiao Z, Cao Z, Cui S, Yang H,

Liang Y, Chen P, Lv Y, Hu C, Lv X, Liu S, Kuang J, Li J,

Wang D, Chang L, A randomized, double-blind,

multicenter Phase II study comparing the efficacy and

safety of oral nemonoxacin with oral levofloxacin in the

treatment of community-acquired pneumonia. J Microbiol

Immunol Infect, 2017. 50(6): p. 811-820.

Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A,

Choudhri SH; Community-Acquired Pneumonia

Recovery in the Elderly Study Group, CommunityAcquired Pneumonia Recovery in the Elderly (CAPRIE):

efficacy and safety of moxifloxacin therapy versus that of

levofloxacin therapy. Clin Infect Dis, 2006. 42(1): p. 73-

West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B,

Oross M, Wu SC, Fowler C, Morgan N, Kahn JB,

Levofloxacin compared with imipenem/cilastatin followed

by ciprofloxacin in adult patients with nosocomial

pneumonia: a multicenter, prospective, randomized,

open-label study. Clin Ther, 2003. 25(2): p. 485-506.

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK,

Brust JCM, Campbell JR, Chang VWL, Falzon D,

Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M,

Kuksa L, Lange C, Laniado-Laborín R, Nahid P,

Rodrigues D, Singla R, Udwadia ZF, Menzies D;

Collaborative Group for the Meta-Analysis of Individual

Patient Data in MDR-TB treatment 2017, Drugassociated adverse events in the treatment of multidrugresistant tuberculosis: an individual patient data metaanalysis. Lancet Respir Med, 2020. 8(4): p. 383-394.

Mancano, M.A., ISMP Adverse Drug Reactions. Hosp Pharm,

52(3): p. 172-176.


Full Text: PDF

Article Metrics

Abstract View : 1700 times
PDF Download : 652 times

Refbacks

  • There are currently no refbacks.